Crossmark

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison

Crossref DOI link: https://doi.org/10.1016/j.abd.2024.05.005

Published Print: 2025-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Selçuk, Leyla Baykal https://orcid.org/0000-0001-7956-4033
Akkuş, Hande Ermiş https://orcid.org/0000-0002-1431-2203
Akşan, Burak https://orcid.org/0000-0002-3052-5014
Arıca, Deniz Aksu https://orcid.org/0000-0003-3755-4325
License Information

Text and Data Mining valid from 2025-03-01

Text and Data Mining valid from 2025-03-01

Version of Record valid from 2024-12-14
More Information

This article is maintained by: Elsevier

Article Title: Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison

Journal Title: Anais Brasileiros de Dermatologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.abd.2024.05.005

Content Type: article

Copyright: © 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U.